EVAXION BIOTECH A/S (EVAX) Stock Analyst Earnings Estimates
NASDAQ:EVAX - Nasdaq - US29970R2040 - ADR - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 73K | 6.672M 9,039.73% | 6.77M 1.47% | 20.34M 200.44% | 27.2M 33.73% | 87.661M 222.28% | 50.329M -42.59% | 29.722M -40.94% | 68.958M 132.01% | 76.898M 11.51% | |||
| EBITDA YoY % growth | -25.49M -54.83% | -24.693M 3.13% | -21.582M 12.60% | -11.22M 48.01% | -5.1M 54.55% | -15.3M -200.00% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -25.834M -55.93% | -25.264M 2.21% | -22.197M 12.14% | -13.304M 40.06% | -10.102M 24.07% | 1.092M 110.81% | 4.873M 346.25% | 63.009M 1,193.02% | 23.288M -63.04% | 655.86K -97.18% | 35.783M 5,355.89% | 37.957M 6.08% | |
| Operating Margin | N/A | N/A | -30,406.85% | -199.40% | -149.22% | 5.37% | 17.92% | 71.88% | 46.27% | 2.21% | 51.89% | 49.36% | |
| EPS YoY % growth | -12.50 74.34% | -9.80 21.60% | -8.20 16.33% | -5.89 28.23% | -2.24 61.87% | 0.70 131.36% | 0.05 -92.75% | 3.37 6,500.00% | 1.22 -63.64% | 0.05 -95.83% | 1.89 3,600.00% | 2.19 16.22% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.96 -147.35% | -0.66 -144.20% | -0.46 23.50% | -0.10 49.00% | -0.12 96.91% | 0.05 107.69% | 0.20 144.44% | 0.21 310.00% | 0.23 291.67% |
| Revenue Q2Q % growth | 1.693M | 3.264M 6,300.00% | 3.315M 2,052.60% | 3.366M 11.57% | 3.596M 112.40% | 6.222M 90.63% | 6.426M 93.85% | 6.63M 96.97% | 7.803M 116.99% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.021M 30.77% | -3.933M 10.53% | -4.026M 12.12% | -4.049M -133.93% | -4.098M -35.65% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.20 90.48% | -1.46 | 1.26 | 86.32% |
| Q2 2024 Q2Q % growth | -0.60 71.43% | -1.99 | 1.39 | 69.83% |
| Q1 2024 Q2Q % growth | 1.50 162.50% | -2.83 | 4.33 | 152.99% |
| Q4 2023 Q2Q % growth | -1.60 44.83% | -1.63 | 0.03 | 1.96% |
| Q3 2023 Q2Q % growth | -2.10 12.50% | -1.99 | -0.11 | -5.58% |
| Q2 2023 Q2Q % growth | -2.10 -5.00% | -2.19 | 0.09 | 4.24% |
| Q1 2023 Q2Q % growth | -2.40 4.00% | -2.45 | 0.05 | 1.96% |
| Q4 2022 Q2Q % growth | -2.90 25.64% | -2.69 | -0.21 | -7.97% |
| Q3 2022 Q2Q % growth | -2.40 11.11% | -2.72 | 0.32 | 11.77% |
| Q2 2022 Q2Q % growth | -2.00 44.44% | -3.05 | 1.05 | 34.49% |
| Q1 2022 Q2Q % growth | -2.50 -8.70% | -3.33 | 0.83 | 24.97% |
| Q4 2021 Q2Q % growth | -3.90 -50.00% | -2.99 | -0.91 | -30.35% |
| Q3 2021 Q2Q % growth | -2.70 | -3.43 | 0.73 | 21.38% |
| Q2 2021 Q2Q % growth | -3.60 | -2.99 | -0.61 | -20.32% |
| Q1 2021 Q2Q % growth | -2.30 | -3.06 | 0.76 | 24.84% |
| Q4 2020 Q2Q % growth | -2.60 | -2.55 | -0.05 | -1.96% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 3.017M | 1.089M | 1.928M | 177.04% |
| Q2 2024 Q2Q % growth | 154K | 53.04K | 100.96K | 190.35% |
| Q1 2024 Q2Q % growth | 51K | 37.74K | 13.26K | 35.14% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -357.46% | -357.46% | 11.91% | -340.46% |
| Revenue | 765.68% | 765.68% | 84.82% | 84.82% |